PGEN catalyst calendar

PRECIGEN, INC.

Upcoming catalysts
3
Cash runway
2.6 months
Cash & investments
$38M

PRECIGEN, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on October 26, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Cash runway is approximately 2.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
October 26, 2026 est. Next quarterly earnings (projected) Earnings —
November 11, 2026 PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer Trial Milestone Phase 2
December 2, 2027 Zopa Retreatment and Vector Shedding in Adults With RRP Trial Milestone Phase 4

Track PGEN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open PGEN in the tracker

Recent history

DateEventTypePhase
August 4, 2026 Quarterly results filed (8-K) Earnings —
June 24, 2026 8-K filed: Leadership change Corporate —
May 13, 2026 Quarterly results filed (8-K) Earnings —
March 25, 2026 Quarterly results filed (8-K) Earnings —
November 13, 2025 Quarterly results filed (8-K) Earnings —
September 3, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
August 18, 2025 8-K filed: Reg FD disclosure Filing —
August 18, 2025 8-K filed: Material agreement Corporate —
June 30, 2025 8-K filed: Leadership change Corporate —
May 14, 2025 Quarterly results filed (8-K) Earnings —
December 15, 2024 Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Trial Milestone Phase 1
August 1, 2024 PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS Trial Milestone Phase 1
June 5, 2024 Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis Trial Milestone Phase 1/Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.